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Treatment of hepatitis B virus-associated membranous
nephropathy with recombinant alpha-interferon
CHING-YUANG LIN
Department of Pediatrics, Veterans General Hospital- Taipei, Taiwan, Republic of China
Treatment of hepatitis B virus-associated membranous nephropathy
with recombinant alpha-interferon. An open, randomized trial study on
the therapeutic effect of recombinant a-interferon (IFNa) in 40 patients
with hepatitis B virus membranous nephropathy (HBVMN) was con-
ducted. All were pathologically proven to have HBVMN which showed no
response to corticosteroid treatment represented by persistent heavy
proteinuria. Both HBeAg and HBsAg were positive in all, Group 1 was
composed of 20 patients who were treated with recombinant IFNa (5
subjects, body wt < 20 kg; 8 subjects, body weight  20 kg) by subcutaneous(s.c.) injection three times a week for 12 months. In group 2 there were 20
patients who received supportive treatment only. At the end of the third
month of treatment, all patients in Group 1 were free of proteinuria. In
contrast, 10 patients (50%) in Group 2 had persistent heavy proteinuria
and another 10 patients (50%) had light proteinuria with exacerbation
during respiratory tract infection. At the end of the twelfth month, 8
patients (40%) in Group 2 still had persistent heavy proteinuria and 12
patients (60%) had light proteinuria with frequent relapses. Eight patients(40%) in Group 1 had HBeAg seroconversion between the fourth and
sixth months and HB5Ag seroconversion between the tenth and twelfth
months. HBe seroconversion only [HBeAg (—)tHBsAg (+)] was found in
four patients. Four patients had no change in HBV serological markers
[HBeAg (+)/HB5Ag (+)]. The remaining 4 patients had HBeAg (—)/
HBeAb (+) HBsAg (—)/HBsAb (—) at the end of the twelfth month. In
contrast, there was no seroconversion of HBeAg (+)/HBsAg (+) in
Group 2 patients. Flu-like symptoms were found in all patients during the
first two weeks of IFNa treatment and disappeared spontaneously.
Psychiatric problems were late side-effects found in 30% of patients which
disappeared when the dosage of IFN was reduced. These results suggest
that IFNa therapy is of value in complete resolution of heavy proteinuria,
and provides some benefit in seroconversion of HBeAg (+ )/HBsAg (+) in
children with HBVMN.
HBVMN is treated with immune inhibitory drugs. Our previous
report demonstrated that the outcome of HBVMN patients
receiving corticosteroid treatment was not favorable [6]. Thus, we
tried to treat HBVMN patients with the regiment of anti-viral
agent.
Certain researchers have shown that interferon-a (IFNa) has
an antiviral effect in in vitro studies [9—12]. Some studies also
demonstrated that IFNa therapy could provide HBe seroconver-
sion [12, 13]. The combined presence of heavy proteinuria and
active HBV proliferation in patients with HBVMN may imply that
IFNa can be an appropriate therapy. In July 1990, I first presented
the preliminary result of IFNa treatment in children with HB-
VMN who had failed corticosteroid treatment, as evidenced by
persistent heavy proteinuria [14]. The results showed that IFNa
treatment given by subcutaneous (s.c.) injection with dosage less
than 3 million units three times per week injection for six months
was ineffective [14]. In contrast, when the dose of IFNa was
increased to 5 million units or given more than three times per
week, the disappearance of proteinuria and HBeAg seroconver-
sion was noted [141. One year after IFNcs treatment, 4 of 10
patients also had hepatitis B surface Ag (HBsAg) seroconversion
[141. These preliminary results encouraged me to conduct a
randomized clinical trial of IFNa in children with HBVMN who
had failed corticosteroid treatment as evidenced by persistent
heavy proteinuria.
Methods
Patient selection
Human infection with hepatitis B virus (HBV) may lead to
acute and chronic hepatitis, liver cirrhosis and/or hepatocellular
carcinoma [1—3] or membranous nephropathy (HBVMN) [4—8].
The HBVMN is transmitted horizontally [5]. It remains uncertain
why some patients with HBV infection develop HBVMN while
others do not.
Several studies have indicated that HBVMN may progress into
chronic renal failure in certain patients [5, 7 ,9—11]. The risk of
developing chronic renal failure, protracted disease course, and
significant morbidity have pushed investigators to search for
specific and effective treatment for this disease. Traditionally,
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From January 1988 to December 1991, forty children aged
under 14-years-old who were suffering from HBVMN with ne-
phrotic syndrome (NS) or heavy proteinuria proven by renal
biopsy were included in the study. They were randomized into two
groups by a random table. Before entering this study, all patients
had received prednisolone with a dose of 2 mg/kg/day orally for
more than two months and failed to improve their NS and
proteinuria. All had normal serum creatinine (Sr) level and
blood pressure.
The kidney biopsy specimen obtained from each patient was
divided into three parts for light, immunofluorescence, and elec-
tron microscopic studies [5—7]. HBsAg was stained with polyclonal
rabbit anti-HBs (Dako Corporation, Santa Barbara, CA, USA)
and monoclonal mouse IgG anti-HBs antisera by an indirect
immunofluorescent technique [5]. For the immunofluorescent
detection of HBcAg in tissues, a 4 m thick cryostat section was
stained with rabbit anti-HBc antibody up to 1600 times dilution
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Fig. 1. A. Stage II membranous nephropathy
with diffuse thickening of the glomendar capillary
walls (HE stain, x400). B. Immunofluorescence
reveals 3 + granular deposition of HBeAg
along the glomerular capillary walls (IF stain
for HBeAg with FITC-conjugated anti-HBe
IgG monoclonal antibody) in the same patient.
C. Viral-like particles were identified within
subepithelial deposits in the same patient (x
40,000).
Study design and study protocol
(Dako Corporation) and HBeAg was stained with FITC-conju-
gated IgG monoclonal anti-HBe antibody [10]. For negative
control, the anti-HBe, anti-HBs and anti-HBc antibodies were
replaced by phosphate buffered saline (PBS).
The criteria for diagnosis of HBVMN were as follows: (1) renal
biopsy showing membranous glomerular thickening (Fig. 1A) and
immunofluorescent staining demonstrating diffuse granular capil-
lary membranous deposits of at least one of HBsAg, HBcAg and
HBeAg (Fig. 1 B, C); (2) serum HBsAg positive; (3) abnormal
urinalysis; (4) no evidence of other viral infections such as
cytomegalovirus or Epstein-Barr virus. The criteria of NS in-
cluded: (1) heavy proteinuria greater than 40 mg/M2/hr deter-
mined quantitatively on a 24-hour overnight urine sample; (2)
hypoalbuminemia less than 2.5 g/dl; (3) puffy face and/or gener-
alized edema. "Heavy proteinuria" was defined as any patient
with only the first criterion. "Light proteinuria" was defined as 4
mg/M2/hr to 40 mg/M2/hr proteinuria. "Free of proteinuria" was
defined as proteinuria less than 4 mg/M2/hr.
An open randomized clinical trial was designed as follows. All
subjects were hospitalized and received renal biopsy. When renal
biopsy confirmed HBVMN, the patients were randomly assigned
to either IFNa or supportive therapy. In group 1 the patients were
treated with rIFNa2b (Intron A, Schering-Plough Co., USA) 5 j
if body weight was less than 20 kg or 8 when body weight was
over 20 kg, by s.c. injection three times per week for one year. The
20 patients in group 2, the control group, received only supportive
treatment for one year. Corticosteroid and immunosuppressive
agents were prohibited; however, other treatments were allowed
to be given. All medications were contained in sealed, completely
opaque envelopes numbered in sequence according to a table of
random numbers. The enrollment of new patients ended in
December 1991, when the planned number of 20 patients in both
groups was reached. This was considered sufficient to have a
power of 0.80 for demonstrating a 0.05 increase in the cumulative
proportion of clinical response in control group versus a 0.40
increase in the IFNa group at month 12, using a two-tailed
I'
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Group 1
(N= 20)
Group 2
(N = 20) P
Mean age years 6.2 2.4 6.8 2.1 NS
Sex (male/female) 15/5 14/6 NS
Previous length of prednisolone 4.0 1.0 4.1 0.8 NS
treatment months
Duration of proteinuria months 5.2 1.4 5.4 1.8 NS
Magnitude of proteinuria 4.1 0.8 4.0 0.6 NS
Serum Cr mg/dl 1.2 0.4 1.1 0.3 NS
Serum albumin g/dl 1.9 0.2 2.0 0.2 NS
Cr ml/min/1.73 m2 116.4 7.6 114.9 8.2 NS
Hypertension
present 0 0 NS
absent 20/20 20/20 NS
Histological grading a scores 2.1 0.5
(1—3)
2.0 .4
(1—3)
NS
a The glomerular changes were classified into four stages [22] (stage Ito
stage IV as grade scores of 1 to 4)
statistical test performed at 0.05 significance level. In the final
analysis, serum HBV serological markers including HBeAg, HBeAb,
HBsAg, HBsAb, HBV DNA, serum biochemistry [glucose, urea,
creatinine, total proteins, albumin, total bilirubin, aspartate trans-
minase (ALT, AST) and gamma GT], whole blood analyses
(hemoglobin, hematocrit, white cell count and differential count,
and platelets) and 24 hour urine protein and creatinine clearances
(Ccr) were assessed in samples collected from each subject of
both groups, on the day immediately before treatment (day 0),
and on days 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and
360.
HBV virological markers
Sera separated soon after venesection were stored at —70°C.
Serum HBsAg, anti-HBsAb, HBeAg, anti-HBeAb, anti-HBcAb
and HBV DNA were measured by radioimmunoassay (Abbott
hepatitis B diagnostic kits, and Abbott hepatitis B viral DNA RIA
kit; Abbott Laboratory, Abbot Park, IL, USA). Anti-IFN Ab was
detected by biological assay [12].
Method of creatinine clearance
Timed urine collections for the determination of creatinine
(Cr) were made 24 hours from 7 a.m. to 7 a.m. of the next day. In
the morning the urine specimen was submitted to the central
laboratory together with measurements of the subject's height and
weight. The creatinine clearance (Car) value was corrected to
body surface area of 1.73 m2. A fasting blood sample was then
drawn. Serum and urinary creatinine were determined by Beck-
man Creatinine Analyzer 2 (Beckman Instruments, Inc., Fuller-
ton, CA, USA).
Follow-up
After the end of the clinical trial, the frequency of follow-up
and of laboratory tests and procedures was the same for both
groups. Each patient every month came to the outpatient clinic.
At each visit, blood pressure, urinalysis, 24-hour urine protein,
hemogram including total white cell count, differential count,
hemoglobin and platelet count, and biochemical parameters
including liver and renal function test were taken.
Statistics
Data are expressed as mean SD. Statistical comparison of the
data was carried out using the unpaired Student's t-test and
chi-square test between the groups and paired Student's t-test
within each group. When the variance was not normally distrib-
uted, the non-parametric f-test was used to compare the differ-
ence. Serial data were examined by analysis of variance.
Results
Evaluation of IFNa treatments by serial detection of HBV markers
and proteinuria at different time intervals
The patients were divided into two groups, each group consist-
ing of 20 children. Group 1 patients received IFNa treatment, and
group 2 was the control group. The clinical characteristics of both
groups are summarized in Table 1. There was no significant
difference between the two groups. The serum creatinine levels
were within normal range in all patients. None had hypertension.
All patients in both groups had HBeAg (+)/HBsAg (+) and
heavy proteinuria before treatment. Six cases in group 1 and 5
cases in group 2 had mild elevation of aldosterone (less than 150
lU/liter) before treatment. Two months after IFNa treatment in
group 1 patients, heavy proteinuria disappeared in 16 patients and
mild proteinuria was found in 4 cases (20%). In contrast, 12 of 20
cases (60%) in group 2 had persistent heavy proteinuria and 8
cases (40%) had light proteinuria with exacerbation during upper
respiratory tract infection. At the end of the third month, all
patients in group 1 were free of proteinuria. In group 2, 10 cases
(50%) still had persisted heavy proteinuria and another 10 cases
(50%) had light proteinuria which showed exacerbation during
upper respiratory tract infection. Up to the end of the twelfth
month, all patients in group 1 were free of proteinuria with no
relapse from the end of third month. However, 6 cases (30%) had
persisted heavy proteinuria, 12 cases (60%) had mild proteinuria
with frequent relapses and only 2 cases (10%) were free of
proteinuria in group 2 (Table 2).
The changes of HBV serological markers in patients who
responded to IFN therapy are shown in Figure 2. The HBeAg
disappeared around the fourth to fifth month followed by HBeAb
which appeared one month later. Then the HBsAg disappeared
around the tenth to twelfth month. HBsAb appeared around the
eleventh to twelfth month. In group 1, eight cases (40%) followed
this course. There was also no relapse after one year follow-up.
Four cases were serum HBeAg (—)/HBeAb (+), HBsAg (—)I
HBsAb (—). Four cases were only HBeAg seroconversion with
persistent HBs antigenemia. The other 4 cases had no change in
HBV serological marker with persistent HBeAg (+). In group 2,
after the end of the twelfth month, all cases still had HBeAg
(+)/HBsAg (+) in sera.
After the first month of IFNa treatment, the aldosterone level
was returned to the normal range in 18 of 20 of group 1 patients
who had elevated aldosterone before treatment. No elevation of
aldosterone level was found during the course of IFNa treatment
in group 1 patients. As in group 1 patients, the aldosterone levels
returned to normal in group 2 patients who had elevated aldoste-
rone in the first four months of observation.
Side-effects of IFNc therapy
The early side-effects of IFNa that appeared during the first
three months of treatment are listed in Table 3. At the first week
Table 1. Clinical and laboratory characteristics of HBVMN children in
the two groups
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Table 2. Serial changes of hepatitis B markers and proteinuria between two groups of HBVMN patients (N = 20 in each group)
Before IFNa After IFNa Follow-up
3 months 6 months 9 months 12 months 24 months
Group Group Group Group Group Group Group Group Group Group Group Group
2 2 1 2 1 2 1 2 1 2 1 2
Proteinuria
>40 mg/M2/hr 20 20 0 10 0 8 0 7 0 6 0 3
4-40 mg/M2/hr
(100%)
0
(100%)
0 4
(20%)
(50%)
10
(50%)
2
(10%)
(40%)
12
(60%)
0
(35%)
12
(60%)
0
(30%)
12
(60%)
(15%)
0 10
(60%) (65%)
<4 mg/M2/hr 0 0 16
(80%)
0 18
(90%)
0 20°
(100%)
ia
(5%)
20C
(100%)
2°
(10%)
20° 7°
(100%) (35%)
HB5Ag (+)
HBeAg(+) 20 20 17 20 10 20 8' 20b 4d 20d 20f
HBeAb(+) (100%) (100%) (85%) (100%) (50%) (100%) (40%) (100%) (20%) (100%) (20%) (100%)
HBeAg(+) 0 0 1 0 2 0 2 0 0 0 0 0
HBeAb(+)
HBeAg(—) 0 0
(5%)
1 0 (10%)8 0 (10%)8 0 4 0 5 0
HBeAb(+)
HB5Ag(—)
(5%) (40%) (40%) (20%) (25%)
HBe(—)
HB5Ag(—) 0 0 0 0 0 0 2 0 4 0 0 0
HBsAg(+)
Serum Cr mg/dl
0
1.2
0 0 0
1.2
0 0
1.2
0
1.2
0 0
1.2 1.4
Ccr ml/min/1.73 116.4 114.9 114.2 110.4 106.2 104.2 101.8 100.1 108.4 98.4 102.4 89.6
m2 ±7.6 ±8.2 ±7.2 ±6.4 ±6.8 ±8.2 ±8.1 ±7.5 ±6.4 ±7.4 ±6.3
ElevatedALT 6
(30%)
5
(25%)
0 5
(25%)
0 5
(25%)
0 3
(15%)
0 2
(10%)
0 2
(10%)
Group 1 was the test group with IFNcs; Group 2 was control group; Follow-up included both groups after the initial study without IFNa treatment.
Both groups previously had prednisolone treatment only.
Comparison between test and control groups was examined by using (chi-square) test: a,c.d,f P < 0.01; b.c P < 0.05
after IFNa treatment, all cases (100%) experienced a flu-like
syndrome. Sixteen patients (80%) had fever, and body tempera-
ture was over 39°C in 8 of 16 patients. The fever subsided
spontaneously after the third week of IFNa therapy in each case.
The late side-effects appeared after six months of IFNa therapy.
There was no hair and weight loss or a decrease of white blood
cells and platelets. The most important late side-effects were
psychiatric problems. Six patients (30%) developed anxiety and
loss of interest, 4 (20%) had depression, and 3 (15%) had suicidal
ideation. When these adverse psychiatric effects appeared, the
dosage of IFNa was decreased immediately. These side effects
disappeared in all cases quickly after reducing the dose of IFN.
There was an absence of hematological, infectious and autoim-
mune adverse effects. Abnormal liver function and systemic side
effects such as fatigue, myalgia, low grade fever, headache and
anorexia were also absent. Anti-IFNaAb was checked and only 4
cases (20%) had low levels of Ab during the study period. None of
them was unresponsive to IFNa treatment.
Follow-up
After this one year IFNcs clinical trial, all patients were
continuously followed up every month in the outpatient clinic.
The results of one year follow-up (24th month) showed that all
patients in group 1 were free of proteinuria. However, in group 2
patients, 3 patients (15%) still had heavy proteinuria. The pro-
teinuria was exacerbated during upper respiratory tract infection.
Ten cases (50%) with light proteinuria and only seven (35%) free
of proteinuria were noted as shown in Table 1. Eleven cases in
group 1 after the end of IFNcv treatment and one year follow-up
(24th month) had HBeAg and HBsAg seroconversion. In the
remaining 9 cases, 4 persisted with HBsAg (+)/HBeAg (+) and 5
only had HBeAg seroconversion but were still with HBsAgemia.
In the group 2 cases 24 months after starting this clinical trial, all
persisted with HBeAg (+)/HBsAg (+).
Discussion
In the present study, first, heavy proteinuria in 20 patients with
HBVMN (group 1) disappeared within three months after start-
ing IFNa treatment. Eight cases (40%) had complete HBV
seroconversion from HBeAg (+)/HBeAb (—), HBsAg (+)/HB-
sAb (—) to HBeAg (—)/HBeAb (+), HBsAg (—)IHBsAb (+). By
contrast, in the control group (group 2)10 patients (50%) had
persistent heavy proteinuria and another 10 cases (50%) had
heavy proteinuria off and on up to 12 months later. These results
suggest that IFNa may be of clinical value in the treatment of
children with HBVMN. IFNa can be very effective in the resolu-
tion of proteinuria in HBVMN and in providing HBV serological
seroconversion in some cases.
The therapeutic effect of IFNa on HBVMN is inconsistent
[13—18}. All except those with membranoproliferative glomerulo-
nephritis had clinical improvement of edema, hypoalbuminemia
and proteinuria after IFNa therapy. Virus replication was sup-
pressed as shown by a decrease in HBV DNA or DNA polymerase
activity. The studies of Lisker-Melmann et al and Man et al
demonstrated that of the three children treated, the HBsAg titer
decreased in one [10] and HBeAg became seroconversion in two
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children [15, 16]. In my earlier studies, the results of IFNa
treatment in children with HBVMN who had failed corticosteroid
treatment associated with persisted heavy proteinuria were inef-
fective both low dose IFNa (3 million units) or high dose (5
million units) treatment given by s.c. injection for six months [14J.
In contrast, when dosage and course were increased, the results
indicated that not only HBeAg seroconversion but also HBsAg
seroconversion was found in 40% (8 of 20) of patients. The major
point is that the dosage of IFN in this study to treat HBVMN was
higher than that used in other works [13—18]. Our preliminary
data indicate that only high doses of IFNa could provide both
HBeAg and HBsAg seroconversion. The higher dosage of IFN
not only had an anti-viral effect but also an immunomodulatory
effect [19—21]. This is the reason a high dose of IFNa was used in
this clinical trial.
In the clinical trial of IFNa for the treatment of HBV-infected
liver disease the decrease of aldosterone levels to normal range
was only used as a therapeutic parameter. However, our previous
data indicated that aldosterone levels in HBVMN patients might
spontaneously return to normal within six months after onset of
nephritis symptoms. This is the reason why the aldosterone level
is not used as a parameter for evaluating the effectiveness of
IFNa.
According to the side effects, fatigue, anorexia, nausea, head-
ache and fever occurred in almost all patients during the first to
second weeks after IFNa treatment, but all of them responded
Fatigue 20 (100%)
Anorexia 20 (100%)
Nausea 18 (90%)
Headache 18 (90%)
Fever 16 (80%)
Chills 12 (60%)
Myalgias 18 (90%)
Arthralgias 8 (40%)
Backache 6 (30%)
Diarrhea 0
Abdominal cramps 0
Impaired concentration 12 (60%)
Reduced attention span 12 (60%)
Difficulty sleeping 6 (30%)
well to the analgesic treatment and spontaneously disappeared
after the third to fourth week of IFNa treatment. The other early
side effects of IFNn also spontaneously disappeared within the
first three months without reducing the IFNa dosage. Therefore,
at this dosage and for the duration adopted in this trial, the higher
IFNo did not produce severe intolerable early side-effects in
patients who were Chinese children. The late side-effects ap-
peared after six months of IFNc therapy. Six patients (30%)
developed transient psychiatric problems including anxiety, loss of
interest, depression and suicidal ideation, but all of them disap-
peared after the dosage of IFNa was reduced. In no case did
IFNa have to be stopped or even reduced by more than 50%.
Complete hemogram was checked regularly in each IFNa treated
patient. There was no bone marrow suppression, nor were there
any differences between before and during IFN treatment. These
results are quite different from those in adult patients. Bone
marrow suppression with leukopenia was noted, and the dosage of
IFNcx had to be stopped or reduced by more than 50% in adult
patients using the same protocol (data not shown). The late side
effects were also different between children and adults (data not
shown). The reason why Chinese patients who are children seem
to tolerate the IFN treatment well is unknown. However, when
patients had psychiatric adverse effects, the dosage of IFNa
needed to be decreased immediately.
In conclusion, IFNa is effective in the complete resolution of
proteinuria in HBVMN patients. Forty percent of the cases
showed HBV seroconversion. Since the tolerance of IFNa in
children was acceptable in this study, we suggest that heavy
proteinuria appeared and persisted for more than two months in
patients with HBVMN, a trial with IFNa treatment is indicated,
especially in the high prevalance area of HBV infection.
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